vs
Apellis Pharmaceuticals, Inc.（APLS）与ONTO INNOVATION INC.（ONTO）财务数据对比。点击上方公司名可切换其他公司
ONTO INNOVATION INC.的季度营收约是Apellis Pharmaceuticals, Inc.的1.1倍（$218.2M vs $199.9M），ONTO INNOVATION INC.净利率更高（12.9% vs -29.5%，领先42.4%），Apellis Pharmaceuticals, Inc.同比增速更快（-5.9% vs -13.5%），ONTO INNOVATION INC.自由现金流更多（$82.0M vs $-14.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs 2.6%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Onto Innovation是一家美国半导体企业，2019年由Rudolph Technologies与Nanometrics合并组建，为微电子制造行业提供生产工艺、工艺控制相关设备及配套软件解决方案，是全球半导体制造支撑领域的重要供应商。
APLS vs ONTO — 直观对比
营收规模更大
ONTO
是对方的1.1倍
$199.9M
营收增速更快
APLS
高出7.6%
-13.5%
净利率更高
ONTO
高出42.4%
-29.5%
自由现金流更多
ONTO
多$96.3M
$-14.3M
两年增速更快
APLS
近两年复合增速
2.6%
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $218.2M |
| 净利润 | $-59.0M | $28.2M |
| 毛利率 | — | 50.7% |
| 营业利润率 | -25.6% | 10.9% |
| 净利率 | -29.5% | 12.9% |
| 营收同比 | -5.9% | -13.5% |
| 净利润同比 | -62.2% | -46.8% |
| 每股收益（稀释后） | $-0.40 | $0.57 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSONTO
| Q4 25 | $199.9M | — | ||
| Q3 25 | $458.6M | $218.2M | ||
| Q2 25 | $178.5M | $253.6M | ||
| Q1 25 | $166.8M | $266.6M | ||
| Q4 24 | $212.5M | $263.9M | ||
| Q3 24 | $196.8M | $252.2M | ||
| Q2 24 | $199.7M | $242.3M | ||
| Q1 24 | $172.3M | $228.8M |
净利润APLSONTO
| Q4 25 | $-59.0M | — | ||
| Q3 25 | $215.7M | $28.2M | ||
| Q2 25 | $-42.2M | $33.9M | ||
| Q1 25 | $-92.2M | $64.1M | ||
| Q4 24 | $-36.4M | $48.8M | ||
| Q3 24 | $-57.4M | $53.1M | ||
| Q2 24 | $-37.7M | $52.9M | ||
| Q1 24 | $-66.4M | $46.9M |
毛利率APLSONTO
| Q4 25 | — | — | ||
| Q3 25 | — | 50.7% | ||
| Q2 25 | — | 48.2% | ||
| Q1 25 | — | 53.7% | ||
| Q4 24 | — | 50.2% | ||
| Q3 24 | — | 54.1% | ||
| Q2 24 | — | 52.9% | ||
| Q1 24 | — | 51.7% |
营业利润率APLSONTO
| Q4 25 | -25.6% | — | ||
| Q3 25 | 48.7% | 10.9% | ||
| Q2 25 | -18.6% | 12.7% | ||
| Q1 25 | -50.0% | 23.7% | ||
| Q4 24 | -12.3% | 16.1% | ||
| Q3 24 | -24.0% | 21.0% | ||
| Q2 24 | -14.7% | 20.2% | ||
| Q1 24 | -36.0% | 18.7% |
净利率APLSONTO
| Q4 25 | -29.5% | — | ||
| Q3 25 | 47.0% | 12.9% | ||
| Q2 25 | -23.6% | 13.4% | ||
| Q1 25 | -55.3% | 24.0% | ||
| Q4 24 | -17.1% | 18.5% | ||
| Q3 24 | -29.2% | 21.0% | ||
| Q2 24 | -18.9% | 21.9% | ||
| Q1 24 | -38.5% | 20.5% |
每股收益（稀释后）APLSONTO
| Q4 25 | $-0.40 | — | ||
| Q3 25 | $1.67 | $0.57 | ||
| Q2 25 | $-0.33 | $0.69 | ||
| Q1 25 | $-0.74 | $1.30 | ||
| Q4 24 | $-0.30 | $0.98 | ||
| Q3 24 | $-0.46 | $1.07 | ||
| Q2 24 | $-0.30 | $1.07 | ||
| Q1 24 | $-0.54 | $0.94 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $603.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $2.0B |
| 总资产 | $1.1B | $2.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSONTO
| Q4 25 | $466.2M | — | ||
| Q3 25 | $479.2M | $603.1M | ||
| Q2 25 | $370.0M | $217.5M | ||
| Q1 25 | $358.4M | $203.7M | ||
| Q4 24 | $411.3M | $212.9M | ||
| Q3 24 | $396.9M | $188.7M | ||
| Q2 24 | $360.1M | $172.6M | ||
| Q1 24 | $325.9M | $190.9M |
总债务APLSONTO
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
股东权益APLSONTO
| Q4 25 | $370.1M | — | ||
| Q3 25 | $401.2M | $2.0B | ||
| Q2 25 | $156.3M | $2.0B | ||
| Q1 25 | $164.2M | $1.9B | ||
| Q4 24 | $228.5M | $1.9B | ||
| Q3 24 | $237.1M | $1.9B | ||
| Q2 24 | $264.3M | $1.8B | ||
| Q1 24 | $266.7M | $1.8B |
总资产APLSONTO
| Q4 25 | $1.1B | — | ||
| Q3 25 | $1.1B | $2.2B | ||
| Q2 25 | $821.4M | $2.1B | ||
| Q1 25 | $807.3M | $2.1B | ||
| Q4 24 | $885.1M | $2.1B | ||
| Q3 24 | $901.9M | $2.1B | ||
| Q2 24 | $904.5M | $2.0B | ||
| Q1 24 | $831.9M | $2.0B |
负债/权益比APLSONTO
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $83.4M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $82.0M |
| 自由现金流率自由现金流/营收 | -7.1% | 37.6% |
| 资本支出强度资本支出/营收 | 0.1% | 0.6% |
| 现金转化率经营现金流/净利润 | — | 2.95× |
| 过去12个月自由现金流最近4个季度 | $45.0M | $261.3M |
8季度趋势，按日历期对齐
经营现金流APLSONTO
| Q4 25 | $-14.2M | — | ||
| Q3 25 | $108.5M | $83.4M | ||
| Q2 25 | $4.4M | $57.9M | ||
| Q1 25 | $-53.4M | $92.0M | ||
| Q4 24 | $19.4M | $56.0M | ||
| Q3 24 | $34.1M | $67.2M | ||
| Q2 24 | $-8.3M | $65.3M | ||
| Q1 24 | $-133.0M | $57.1M |
自由现金流APLSONTO
| Q4 25 | $-14.3M | — | ||
| Q3 25 | $108.3M | $82.0M | ||
| Q2 25 | $4.4M | $44.2M | ||
| Q1 25 | $-53.4M | $83.7M | ||
| Q4 24 | $19.3M | $51.4M | ||
| Q3 24 | — | $59.2M | ||
| Q2 24 | $-8.4M | $53.0M | ||
| Q1 24 | $-133.3M | $50.2M |
自由现金流率APLSONTO
| Q4 25 | -7.1% | — | ||
| Q3 25 | 23.6% | 37.6% | ||
| Q2 25 | 2.5% | 17.4% | ||
| Q1 25 | -32.0% | 31.4% | ||
| Q4 24 | 9.1% | 19.5% | ||
| Q3 24 | — | 23.5% | ||
| Q2 24 | -4.2% | 21.9% | ||
| Q1 24 | -77.3% | 21.9% |
资本支出强度APLSONTO
| Q4 25 | 0.1% | — | ||
| Q3 25 | 0.0% | 0.6% | ||
| Q2 25 | 0.0% | 5.4% | ||
| Q1 25 | 0.0% | 3.1% | ||
| Q4 24 | 0.0% | 1.8% | ||
| Q3 24 | 0.0% | 3.2% | ||
| Q2 24 | 0.0% | 5.1% | ||
| Q1 24 | 0.2% | 3.0% |
现金转化率APLSONTO
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | 2.95× | ||
| Q2 25 | — | 1.71× | ||
| Q1 25 | — | 1.44× | ||
| Q4 24 | — | 1.15× | ||
| Q3 24 | — | 1.27× | ||
| Q2 24 | — | 1.23× | ||
| Q1 24 | — | 1.22× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
ONTO
| Systems And Software Revenue | $173.8M | 80% |
| Parts Revenue | $23.9M | 11% |
| Service Revenue | $20.5M | 9% |
